We hypothesized that co-expression of separate chimeric receptors in which both CD28 and 41BB were positioned next to the plasma membrane would provide dual tumor antigen-dependent co-stimulation, thereby mitigating tumor-induced CAR T cell dysfunction. Here, TNFRSF9 is linked to neoplasm.